Kevin Judice's guest appearances

Kevin Judice

The Kyle Thiermann Show

Biotech 2050 Podcast

The Drill Down

Elon Musk

Chris Ryan

Mark Titus

Moshe Kasher

Peter Attia

Aaron Alexander

Paul Saladino

Rick Hanson

Lawrence Lessig

Ben Greenfield

Charles Eisenstein

Duncan Trussell

Ceara Lynch

Ralph Lauren

Kelly Brogan

OwlTail

Synopsis: Kevin Judice is the Co-Founder and CEO of DICE Therapeutics, a clinical-stage biopharmaceutical company developing transformative medicines for autoimmune and inflammatory diseases. Kevin trained as an organic chemist in graduate school before beginning his career at Genentech in the early 90s. He talks about stepping into the CEO role for the first time at DICE, the challenges of maintaining a lean startup while avoiding burnout, and how he approaches fundraising. He also shares insights for aspiring entrepreneurs and advice he would give to his younger self.Biography: Kevin Judice currently serves as the co-founder and CEO of DICE Therapeutics. Prior to DICE, he co-founded Achaogen, Inc., where, as the first employee, he was the chief scientific officer and CEO. During his seven-year tenure at Achaogen, Kevin oversaw three rounds of venture financing, steered its growth to 65 full-time employees and established collaborations with DARPA, NIAID, DTRA and BARDA.Prior to Achaogen, he ran medicinal chemistry at Genentech. In the late ‘90s, he was one of the first employees and served as the vice president of chemistry at Theravance, where he led the discovery of Vibativ®.Kevin holds a Ph.D. in organic chemistry from the University of California Los Angeles with Nobel Laureate Donald J. Cram, then did his postdoctoral fellowship at the University of California Berkeley in the laboratories of Peter G. Schultz. He received his B.S. in chemistry from Texas A&amp;M University. Kevin is also a Henry Crown fellow at the Aspen Institute.

Synopsis: Kevin Judice is the Co-Founder and CEO of DICE Therapeutics, a clinical-stage biopharmaceutical company developing transformative medicines for autoimmune and inflammatory diseases. Kevin trained as an organic chemist in graduate school before beginning his career at Genentech in the early 90s. He talks about stepping into the CEO role for the first time at DICE, the challenges of maintaining a lean startup while avoiding burnout, and how he approaches fundraising. He also shares insights for aspiring entrepreneurs and advice he would give to his younger self. Biography: Kevin Judice currently serves as the co-founder and CEO of DICE Therapeutics. Prior to DICE, he co-founded Achaogen, Inc., where, as the first employee, he was the chief scientific officer and CEO. During his seven-year tenure at Achaogen, Kevin oversaw three rounds of venture financing, steered its growth to 65 full-time employees and established collaborations with DARPA, NIAID, DTRA and BARDA. Prior to Achaogen, he ran medicinal chemistry at Genentech. In the late ‘90s, he was one of the first employees and served as the vice president of chemistry at Theravance, where he led the discovery of Vibativ®. Kevin holds a Ph.D. in organic chemistry from the University of California Los Angeles with Nobel Laureate Donald J. Cram, then did his postdoctoral fellowship at the University of California Berkeley in the laboratories of Peter G. Schultz. He received his B.S. in chemistry from Texas A&amp;M University. Kevin is also a Henry Crown fellow at the Aspen Institute.

High-impact oral small molecule therapy in autoimmune disease, Kevin Judice,Co-Founder & CEO,DICE Tx

DICE Therapeutics CEO Kevin Judice, PhD., (DICE), explains the company’s focus on democratizing skin disease therapies. Brunswick (BC) says the business is doing well… but is anyone listening? Chegg (CHGG) sounds the alarm about the current state of higher education in the U.S. The Drill Down with Cory Johnson offers a regular look at the business stories behind stocks on the move. Learn more about your ad choices. Visit megaphone.fm/adchoices

DICE Therapeutics CEO Kevin Judice, PhD., (DICE), explains the company’s focus on democratizing skin disease therapies. Brunswick (BC) says the business is doing well… but is anyone listening? Chegg (CHGG) sounds the alarm about the current state of higher education in the U.S. The Drill Down with Cory Johnson offers a regular look at the business stories behind stocks on the move. Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Ep. 154: DICE Therapeutics CEO Kevin Judice, Brunswick, Chegg

Dr. Kevin Judice holds a bachelor’s degree in chemistry from Texas A&amp;M University and PhD in organic chemistry from the University of California, Los Angeles. He lives in San Francisco, California, United States. Kevin Judice is the chief executive officer of DiCE Molecules. He also serves as the founder and principal of Cloudbreak Consulting and a member of the scientific advisory board at California Institute for Biomedical Research. Previously, he was the founder and chief security officer of Cidara Therapeutics. 

Dr. Kevin Judice holds a bachelor’s degree in chemistry from Texas A&amp;M University and PhD in organic chemistry from the University of California, Los Angeles. He lives in San Francisco, California, United States. Kevin Judice is the chief executive officer of DiCE Molecules. He also serves as the founder and principal of Cloudbreak Consulting and a member of the scientific advisory board at California Institute for Biomedical Research. Previously, he was the founder and chief security officer of Cidara Therapeutics.

#50 Life In The Post-Antibiotic Era Is Going To Suck - Kevin Judice